Patient-Derived First Generation Xenografts of Non–Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized Chemotherapy
Xin Dong, Yuzhuo Wang(BC Cancer Agency), Wan L. Lam(BC Cancer Agency), Calum MacAulay(BC Cancer Agency), John C. English(BC Cancer Agency), Nevin Murray(BC Cancer Agency), Victor Ling(BC Cancer Agency), Kenneth G. Evans(BC Cancer Agency), Janessa Laskin(BC Cancer Agency), Julia Flint(BC Cancer Agency), Peter W. Gout(BC Cancer Agency), John Yee(BC Cancer Agency), Jun Guan(Huazhong University of Science and Technology), Raymond T. Ng(BC Cancer Agency), Stephen Lam
Cited by 195
Related Papers
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Near‐infrared Raman spectroscopy for optical diagnosis of lung cancer
|International Journal of Cancer|2003|811
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Identifying Individuals with Physcian Diagnosed COPD in Health Administrative Databases
|COPD Journal of Chronic Obstructive Pulmonary Disease|2009|664
Identifying Patients with Physician‐Diagnosed Asthma in Health Administrative Databases
|Canadian Respiratory Journal|2009|439